Intra-Cellular Therapies is nearing breakeven, contingent on...

Intra-Cellular Therapies is nearing breakeven, contingent on maintaining a 57% annual growth rate. Its lack of debt, unusual for a pharma company, reduces investment risk.

Market Sentiment Around Loss-Making Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

1954 Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

3177Followers

0Following

7930Visitors